Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST012
MIFTS: 43

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

About this section

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 15
Adenocarcinoma of the Gastroesophageal Junction 71
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4944
NCIt 49 C9296
UMLS 71 C1332166
Sources

Summaries for Gastroesophageal Junction Adenocarcinoma

About this section
MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to gastroesophageal adenocarcinoma and adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are PAK Pathway and Focal Adhesion. The drugs Gefitinib and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Gastroesophageal Junction Adenocarcinoma

About this section

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 gastroesophageal adenocarcinoma 30.9 KDR ERBB2 EGFR
2 adenocarcinoma 30.8 VEGFA MMP9 KDR ERBB2 EGFR
3 helicobacter pylori infection 30.6 PAK1 IL1B EGFR
4 esophagitis 30.5 VEGFA IL1B EGFR
5 exanthem 29.2 VEGFA KDR ERBB2 EGFR CD274
6 gastric adenocarcinoma 28.9 VEGFA SERPINB5 MMP9 KDR IL1B ERBB2
7 esophageal cancer 27.8 VEGFA MMP9 LINC02157 LINC02155 KDR IL1B
8 gastric cancer 27.6 VEGFA SNAI1 SERPINB5 PAK1 MMP9 KDR
9 neutropenia 10.6
10 angiokeratoma of mibelli 10.4 MMP9 KDR
11 dysphagia 10.4
12 mucositis 10.4
13 breast scirrhous carcinoma 10.4 ERBB2 EGFR
14 barrett esophagus 10.3
15 breast metaplastic carcinoma 10.3 ERBB2 EGFR
16 breast malignant phyllodes tumor 10.3 ERBB2 EGFR
17 gastroesophageal reflux 10.3
18 stomatitis 10.3
19 progesterone-receptor negative breast cancer 10.3 ERBB2 EGFR
20 osteosclerotic myeloma 10.3 VEGFA IL1B
21 diarrhea 10.2
22 peptic esophagitis 10.2
23 in situ carcinoma 10.2
24 ovarian carcinosarcoma 10.2 ERBB2 CD274
25 biliary tract cancer 10.2 ERBB2 EGFR
26 odontogenic myxoma 10.2 VEGFA MMP9
27 cervical adenosquamous carcinoma 10.2 KDR EGFR
28 paronychia 10.2 ERBB2 EGFR
29 luminal breast carcinoma 10.2 SNAI1 ERBB2 EGFR
30 radiation proctitis 10.1 VEGFA KDR
31 breast cancer 10.1
32 microinvasive gastric cancer 10.1
33 barrett's adenocarcinoma 10.1
34 recurrent respiratory papillomatosis 10.1 ERBB2 EGFR CD274
35 sick building syndrome 10.1 VEGFA MMP9
36 eales disease 10.1 VEGFA IL1B
37 fallopian tube carcinoma 10.1 VEGFA MMP9 ERBB2
38 mammary paget's disease 10.1 ERBB2 EGFR CD274
39 dupuytren contracture 10.1 VEGFA IL1B
40 epithelioid hemangioendothelioma 10.1 VEGFA KDR
41 gastric ulcer 10.1 VEGFA MMP9 IL1B
42 keratitis, hereditary 10.1 VEGFA MMP9 IL1B
43 adamantinous craniopharyngioma 10.1 VEGFA MMP9
44 soft tissue sarcoma 10.1 VEGFA EGFR
45 chorioamnionitis 10.1 VEGFA MMP9 IL1B
46 gingivitis 10.1 VEGFA MMP9 IL1B
47 primary cutaneous b-cell lymphoma 10.1 VEGFA KDR
48 intrahepatic cholangiocarcinoma 10.1 ERBB2 EGFR CD274
49 angiokeratoma circumscriptum 10.0 VEGFA MMP9 KDR
50 brain edema 10.0 VEGFA MMP9 IL1B

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma
Sources

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

About this section

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.88 CD274
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.88 EGFR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.88 CD274
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.88 CD274
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.88 EGFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 KDR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.88 ERBB2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.88 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.88 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.88 CLDN18
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.88 CLDN18
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.88 CD274
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.88 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.88 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.88 ERBB2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.88 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.88 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.88 CD274
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.88 CD274
20 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.88 CD274 ERBB2 KDR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.88 CLDN18 EGFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.88 CLDN18
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.88 CLDN18
24 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.88 ERBB2 KDR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.88 CLDN18 ERBB2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.88 CLDN18
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 CD274 CLDN18 EGFR ERBB2 KDR

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 CD274 CLDN18 EGFR ERBB2 KDR MMP9
2 respiratory system MP:0005388 9.5 CLDN18 EGFR ERBB2 KDR MMP9 PAK1
3 skeleton MP:0005390 9.32 CD274 CLDN18 EGFR ERBB2 IL1B KDR
Sources

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

About this section

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
5
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
6
nivolumab Approved Phase 2, Phase 3 946414-94-4
7
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
11
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
14
Fluorouracil Approved Phase 3 51-21-8 3385
15
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
16
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1 9903
17
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
20
Rilotumumab Investigational Phase 3 872514-65-3
21 topoisomerase I inhibitors Phase 3
22 Central Nervous System Stimulants Phase 3
23 Opiate Alkaloids Phase 3
24 Appetite Stimulants Phase 3
25 Analgesics Phase 3
26 Antiemetics Phase 3
27 Vitamin B9 Phase 3
28 Folate Phase 3
29 Calcium, Dietary Phase 3
30 Protective Agents Phase 3
31 Antidotes Phase 3
32 Hormones Phase 3
33 Trace Elements Phase 3
34 Vitamins Phase 3
35 Micronutrients Phase 3
36 Vitamin B Complex Phase 3
37 Nutrients Phase 3
38 Hematinics Phase 3
39
s 1 (combination) Phase 2, Phase 3
40
Apatinib Phase 3 811803-05-1
41 Immunologic Factors Phase 3
42 Pharmaceutical Solutions Phase 3
43 Topoisomerase Inhibitors Phase 3
44 Mitogens Phase 3
45 Albumin-Bound Paclitaxel Phase 2, Phase 3
46 Immunoglobulins Phase 3
47 Antibodies Phase 3
48 Antimetabolites Phase 3
49 Anti-Bacterial Agents Phase 3
50 Antibodies, Monoclonal Phase 3

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
2 Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy Completed NCT01243398 Phase 3
3 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
4 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
5 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
6 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT01170663 Phase 3 Placebo;Paclitaxel
7 A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy Completed NCT00917384 Phase 3 Placebo
8 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
9 A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma Completed NCT02178956 Phase 3 BBI608;Paclitaxel
10 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
11 Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
12 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
13 A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting NCT03604991 Phase 2, Phase 3 Carboplatin;Paclitaxel
14 Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine
15 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting NCT03777657 Phase 3 Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU;Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU
16 Phase â…¡/â…¢ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
17 Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI) Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
18 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Recruiting NCT03504397 Phase 3 zolbetuximab;placebo;oxaliplatin;folinic acid;fluorouracil
19 A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) Recruiting NCT03615326 Phase 3 Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
20 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Recruiting NCT01523015 Phase 2, Phase 3
21 A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
22 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
23 Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer Active, not recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
24 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Active, not recruiting NCT02370498 Phase 3 paclitaxel
25 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Active, not recruiting NCT03019588 Phase 3 Paclitaxel
26 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
27 Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction Not yet recruiting NCT03986385 Phase 3 Apatinib Capecitabine Oxaliplatin;Capecitabine Oxaliplatin
28 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
29 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
30 A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine;trastuzumab emtansine
31 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT02525237 Phase 2 Apatinib;S-1
32 A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
33 Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT03083613 Phase 2 Raltitrexed;Paclitaxel
34 A Prospective Study of Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab for Siewert II ，III of HER-2 Positive Adenocarcinoma at Gastroesophageal Junction Unknown status NCT03368131 Phase 2 Trastuzumab;Capecitabine;Oxaliplatin
35 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
36 Phase I/IIa, Single-Arm, Open Study of Apatinib and MASCT in Patients With Advanced Solid Tumors Unknown status NCT02844881 Phase 1, Phase 2 Apatinib
37 Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma Unknown status NCT02848794 Phase 1, Phase 2 Apatinib and Irinotecan
38 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Completed NCT00084617 Phase 2 oxaliplatin;irinotecan hydrochloride;capecitabine
39 A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction Completed NCT01630083 Phase 2 Epirubicin;Oxaliplatin;Capecitabine;Zolbetuximab 800/600 mg/m2;Zolbetuximab 1000 mg/m2
40 A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin
41 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
42 Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter. Completed NCT01360086 Phase 2 cisplatin;fluorouracil;leucovorin calcium
43 A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Completed NCT00253370 Phase 2 BAY 43-9006;docetaxel;cisplatin
44 A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02340975 Phase 1, Phase 2
45 Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02514551 Phase 2 Ramucirumab;Paclitaxel
46 Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02443883 Phase 2 Ramucirumab
47 A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction Completed NCT00073502 Phase 2 OSI-7904L
48 A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients Completed NCT01983878 Phase 2 Ramucirumab
49 Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT) Completed NCT01472029 Phase 2 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab;Post-operative treatment trastuzumab mono therapy
50 Open-label, Single-arm, Multicenter Phase II Trial Investigating Cetuximab in Combination With S-1 and Cisplatin as First-line Treatment for Patients With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT01388790 Phase 2 Cetuximab;Cisplatin;S-1

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Sources

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

About this section
Sources

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

About this section

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

40
Breast, Lung, Lymph Node, Bone, Endothelial, Tongue, Liver
Sources

Publications for Gastroesophageal Junction Adenocarcinoma

About this section

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 331)
# Title Authors PMID Year
1
Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. 61
31721447 2020
2
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. 61
31895837 2020
3
Paraneoplastic Leukemoid Reaction in Gastroesophageal Junction Adenocarcinoma: A Case Report. 61
32001665 2020
4
SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). 61
31989475 2020
5
Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. 61
31977493 2020
6
Endoscopic vacuum assisted closure of esophagogastric anastomosis dehiscence: A case report. 61
31942233 2020
7
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. 61
31802410 2019
8
The expressions and prognostic implications of Twist and E-cadherin in adenocarcinomas of the gastroesophageal junction and proximal gastric carcinoma. 61
31876727 2019
9
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. 61
31676670 2019
10
Baseline neutrophil-lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. 61
31676907 2019
11
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. 61
30671799 2019
12
Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease. 61
31728250 2019
13
Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. 61
31102632 2019
14
Risk factors and patterns of recurrence after curative resection in Gastroesophageal Junction Adenocarcinoma. 61
31488992 2019
15
Obturator hernia and the elderly. 61
30397870 2019
16
Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. 61
31243725 2019
17
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer. 61
31489588 2019
18
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. 61
31142504 2019
19
Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. 61
31234645 2019
20
High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. 61
31425286 2019
21
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. 61
31138725 2019
22
The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. 61
30941657 2019
23
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. 61
30911859 2019
24
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. 61
30515672 2019
25
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. 61
31410344 2019
26
Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. 61
31188215 2019
27
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. 61
30991863 2019
28
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. 61
31126258 2019
29
Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. 61
30499151 2019
30
Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma. 61
31179442 2019
31
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. 61
30470690 2019
32
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population 61
31030487 2019
33
Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study. 61
31069184 2019
34
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. 61
30535535 2019
35
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. 61
30777447 2019
36
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT]. 61
30758590 2019
37
Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. 61
30483986 2019
38
Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. 61
30391577 2019
39
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. 61
30913304 2019
40
Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. 61
30516569 2019
41
Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study. 61
30732125 2019
42
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. 61
31516556 2019
43
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. 61
30120163 2019
44
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? 61
31099690 2019
45
Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. 61
29993360 2019
46
Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma. 61
31002675 2019
47
Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea. 61
30607296 2018
48
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. 61
29508095 2018
49
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. 61
30355453 2018
50
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 61
29703766 2018
Sources

Variations for Gastroesophageal Junction Adenocarcinoma

About this section
Sources

Expression for Gastroesophageal Junction Adenocarcinoma

About this section
Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.
Sources

Pathways for Gastroesophageal Junction Adenocarcinoma

About this section

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
PAK Pathway 63
Show member pathways
 13.17 SNAI1 PAK1 KDR IL1B ERBB2 EGFR
2
Focal Adhesion 1 36
Show member pathways
 12.75 VEGFA PAK1 KDR ERBB2 EGFR
3
T cell receptor signaling pathway 36
Show member pathways
 12.49 PAK1 IL1B EGFR CD274
4
EPH-Ephrin signaling 65
Show member pathways
 12.49 VEGFA PAK1 MMP9 KDR
5
Immune response IL-23 signaling pathway 22
Show member pathways
 12.48 PAK1 IL1B ERBB2 EGFR
6
Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling Pathways 64
Show member pathways
 12.48 VEGFA PAK1 MMP9 KDR CLDN18
7
ErbB signaling pathway 1 36
Show member pathways
 12.39 VEGFA PAK1 KDR ERBB2 EGFR
8
Apoptosis Pathway 70
Show member pathways
 12.3 KDR IL1B ERBB2 EGFR
9
MAPK signaling pathway 36 1
12.3 VEGFA PAK1 KDR IL1B ERBB2 EGFR
10
MicroRNAs in cancer 36
12.26 VEGFA SERPINB5 MMP9 ERBB2 EGFR
11
RhoGDI Pathway 63
Show member pathways
 12.24 VEGFA PAK1 KDR EGFR
12
MAPK Pathway 70
Show member pathways
 11.93 IL1B ERBB2 EGFR
13
Spinal Cord Injury 1
11.91 MMP9 IL1B EGFR
14
S1P3 pathway 1
Show member pathways
 11.87 VEGFA PAK1 KDR
15
EPHA forward signaling 1
Show member pathways
 11.87 VEGFA PAK1 KDR
16
Interleukin-4 and 13 signaling 65
11.86 VEGFA MMP9 IL1B
17
Fluid shear stress and atherosclerosis 36
11.85 VEGFA MMP9 KDR IL1B
18
HIF-1 signaling pathway 36
11.82 VEGFA ERBB2 EGFR
19
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 65
Show member pathways
 11.75 VEGFA ERBB2 EGFR
20
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.74 VEGFA PAK1 KDR
21
Angiogenesis (CST) 4
11.72 SERPINB5 MMP9 KDR
22
Adherens junction 36
11.57 SNAI1 ERBB2 EGFR
23
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.54 PAK1 ERBB2 EGFR
24
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.5 VEGFA MMP9 IL1B
25
Agrin Interactions at Neuromuscular Junction 63
11.44 PAK1 ERBB2 EGFR
26
Proteoglycans in cancer 36
11.41 VEGFA PAK1 MMP9 KDR ERBB2 EGFR
27
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.31 PAK1 MMP9 ERBB2 EGFR
28
Vemurafenib Pathway, Pharmacodynamics 60
11.29 VEGFA KDR EGFR
29
Signaling events mediated by TCPTP 1
Show member pathways
 11.26 VEGFA KDR EGFR
30
Bladder cancer 36 1
11.12 VEGFA MMP9 ERBB2 EGFR
31
G-protein signaling_Rap2B regulation pathway 22
10.87 PAK1 KDR IL1B ERBB2 EGFR
32
VEGF binds to VEGFR leading to receptor dimerization 65
Show member pathways
 10.82 VEGFA KDR
33
Angiogenesis (WikiPathways) 1
10.81 VEGFA MMP9 KDR
Sources

GO Terms for Gastroesophageal Junction Adenocarcinoma

About this section

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.78 PAK1 IL1B ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 KDR ERBB2 EGFR
3 wound healing GO:0042060 9.7 PAK1 ERBB2 EGFR
4 positive regulation of cell proliferation GO:0008284 9.7 VEGFA PAK1 MTA3 KDR IL1B ERBB2
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 VEGFA PAK1 EGFR
6 positive regulation of epithelial cell proliferation GO:0050679 9.63 VEGFA ERBB2 EGFR
7 protein autophosphorylation GO:0046777 9.62 PAK1 KDR ERBB2 EGFR
8 positive regulation of MAP kinase activity GO:0043406 9.61 VEGFA ERBB2 EGFR
9 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.57 VEGFA IL1B
10 astrocyte activation GO:0048143 9.56 IL1B EGFR
11 vascular endothelial growth factor signaling pathway GO:0038084 9.54 VEGFA KDR
12 positive regulation of positive chemotaxis GO:0050927 9.51 VEGFA KDR
13 positive regulation of protein phosphorylation GO:0001934 9.5 VEGFA PAK1 MMP9 KDR IL1B ERBB2
14 regulation of ERK1 and ERK2 cascade GO:0070372 9.43 IL1B ERBB2 EGFR
15 negative regulation of ERBB signaling pathway GO:1901185 9.4 ERBB2 EGFR
16 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.37 VEGFA KDR
17 positive regulation of cell migration GO:0030335 9.23 VEGFA SNAI1 PAK1 MMP9 KDR IL1B

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 VEGFA MMP9 KDR ERBB2 EGFR CLDN18
2 protein tyrosine kinase activity GO:0004713 9.33 KDR ERBB2 EGFR
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KDR ERBB2 EGFR
Sources

Sources for Gastroesophageal Junction Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....